Mulcahy exploratory chemistry
Ended Awarded Last action
- Contract number
- 75N95019F00089
- Awardee
-
Curia Global Inc. UEI ELCNZCS8GEA3
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,804,475
Award facts
- Opportunity
-
- NIHNINDS1701 Solicitation number
- Medicinal Chemistry Support Program for Therapeutic Development (MCSP) Award Notice · Posted Mar 19, 2018
- Medicinal Chemistry Support Program for Therapeutic Development (MCSP) Award Notice · Posted Jun 30, 2017
- Contract value 100% obligated
- $1,804,475.47 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Albany, NY 12212, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$305,309 | |
| Funding Only Action | -$3 | |
| Exercise an Option | $515,228 | |
| Other Administrative Action | $905,711 | |
| Original award | $688,848 |
About this award
This federal contract award is for a Delivery Order (Contract # 75N95019F00089) issued by the National Institute of Neurological Disorders and Stroke (NINDS), a civilian agency, to Curia Global Inc. (doing business as Amri). The award, valued at $1,804,475.47, is for the MULCAHY EXPLORATORY CHEMISTRY project under the Medicinal Chemistry Support Program for Therapeutic Development. The contract type is Cost Plus Fixed Fee, and the ultimate completion date is November 30, 2022. The award does not have a set-aside designation. Curia Global Inc. is a leading global contract development and manufacturing organization (CDMO) that provides a wide range of pharmaceutical research and development services to federal agencies, particularly in the areas of neurology, infectious diseases, and substance abuse.
Quick answers
Who was awarded contract 75N95019F00089?
75N95019F00089 was awarded to Curia Global Inc. by National Institute on Drug Abuse (National Institutes of Health) on May 2, 2019.
How much is contract 75N95019F00089 worth?
The government has obligated $1,804,475 on 75N95019F00089.
Which agency awarded contract 75N95019F00089?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00089, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95019F00089 an order under another contract?
Yes. 75N95019F00089 is a delivery order under HHSN271201800001I, an indefinite delivery contract.
Was contract 75N95019F00089 competed?
The extent of competition for 75N95019F00089 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award